ライフサイエンスコーパス: patients with stage

1 Patients with stage 0 (carcinoma in situ) or stage I (T1

2 urvival of 97.4% (95% CI, 96.0% to 98.8%) in patients with stage 0 or I, only 79.5% (95% CI, 74.2% to

3 A total of 316,114 patients with stage 0 to II breast cancer who underwent

4 For 494 patients with stage 0 to IIB melanoma (mean age, 55 year

5 The evaluable population included 494 patients with stage 0 to IIB melanoma and their skin che

6 Patients with stage 0 to IIB melanoma and their skin-che

7 erated partial breast irradiation (APBI) for patients with stage 0, I, and IIA breast cancer who unde

8 The 5-year event-free survival rates for patients with stages 0 to III breast cancer were 84.48%

9 Patients with stages 0 to III breast cancer were recruit

10 In the intention-to-treat analysis, 67 patients with stage 1 disease (30.7%) and 41 patients wi

11 esults (SEER)-Medicare and NLST datasets for patients with stage 1 disease aged 65 to 74 years.

12 A lower proportion of patients with stage 1 disease and an SVR died from HCC (

13 Patients with stage 1 disease and an SVR were less likel

14 regardless of SVR, were at greater risk than patients with stage 1 disease for liver decompensation (

15 double-blind, outpatient study randomized 54 patients with stage 1 hypertension to receive either chl

16 nsity of 10.3 (5.6) mm/mm2 in the corneas of patients with stage 1 or 2 keratoconus was reduced 51% (

17 o manage elevated low-density lipoprotein in patients with stage 1 to 3 chronic kidney disease.

18 e time of definitive surgery from chemonaive patients with stage 1-3 breast cancer from February, 200

19 Patients with stage 1-3 renal disease (<120 mL . min(-1)

20 in practice globally is in the proportion of patients with stage 1a disease who go on surveillance ra

21 %-92.3%) and 94.4% (95% CI, 83.4%-98.2%) for patients with stage 1A/B disease and 63.2% (95% CI, 36.6

22 incidence, although it may delay recovery in patients with stage 2 AKI.

23 initiation seemed to slow renal recovery in patients with stage 2 AKI.

24 Patients with stage 2 CKD (estimated glomerular filtrati

25 In patients with stage 2 CKD, adjusted mean treatment diffe

26 In patients with stage 2 CKD, adverse events were reported

27 patients with stage 1 disease (30.7%) and 41 patients with stage 2 disease (18.1%) achieved an SVR (P

28 A lower proportion of patients with stage 2 disease and an SVR died from cause

29 However, SVR did not affect whether patients with stage 2 disease developed further EVs (HR,

30 nsation did not differ significantly between patients with stage 2 disease with or without an SVR (12

31 Patients with stage 2 disease, regardless of SVR, were a

32 al distribution in histologic sections of 10 patients with stage 2 invasive breast cancers.

33 Among all patients with stage 2 MHs, 30 of 38 patients (78.9%) had

34 C criteria were applied, 1281 (61%) of those patients with stage 2-3 AKI-UO were misclassified as eit

35 atin (FOLFOX6) for the adjuvant treatment of patients with stage 2-3 colon cancer.

36 ria were amended on Feb 25, 2010, to include patients with stage 2-3 HER2-positive breast cancer who

37 Among patients with stage 2b disease, EFS and OS were signific

38 Patients with stage 2B, 2C, 3B, and 3C melanoma were ran

39 Patients with stage 3 CKD (eGFR >/=30 to <60 mL/min per

40 In patients with stage 3 CKD, adjusted mean treatment diffe

41 In patients with stage 3 CKD, adverse events were reported

42 Patients with stage 3 DCMD (24 patients; 26%) generally

43 decompensation (DC) among HIV/HCV-coinfected patients with stage 3 fibrosis in the short term could b

44 s associated with improvement in survival in patients with stage 3 fibrosis.

45 d, placebo-controlled trial, we enrolled 120 patients with stage 3 nondiabetic CKD.

46 Among all patients with stage 3 or 4 MHs, 42 of 62 (67.7%) had at

47 lind, placebo-controlled trial involving 201 patients with stage 3, 4, or 5 non-dialysis-dependent CK

48 Thus, in nondiabetic patients with stage 3-4 CKD and vitamin D deficiency, vi

49 , double-blind trial, we randomized 42 adult patients with stage 3-4 CKD who were already receiving o

50 Standard ICRS do not improve vision in patients with stage 3-4 keratoconus (Amsler-Krumeich cla

51 ure serum T50 in a prospective cohort of 184 patients with stages 3 and 4 CKD, with a median of 5.3 y

52 amin D reduces left ventricular (LV) mass in patients with stages 3-5 CKD with LV hypertrophy.

53 %-81.1%) and 78.1% (95% CI, 50.0%-91.5%) for patients with stage 3A disease.

54 The OS and MCCSS at 24 months for patients with stage 3B disease were both 50.0% (95% CI,

55 The 5-year survival was similar for patients with stage 4 irrespective of the option of anti

56 Finally, the analysis of NK cells from patients with stage 4 NB suggests that NB conditioning c

57 In intensively treated patients with stage 4 neuroblastoma age 18 months or old

58 emotherapy predicted unfavorable outcome for patients with stage 4 neuroblastoma.

59 without ribavirin) in a prospective study of patients with stage 4 or 5 chronic kidney disease (CKD).

60 high rate of sustained virologic response in patients with stage 4 or 5 chronic kidney disease and HC

61 Chronic hepatitis C virus (HCV) infection in patients with stage 4-5 chronic kidney disease increases

62 ng vitamin D insufficiency and deficiency in patients with stage 5D chronic kidney disease.

63 MI are more favorable compared with those of patients with stage 5D CKD and approach those of the gen

64 differ among renal transplant recipients vs patients with stage 5D CKD or those without CKD has not

65 tion >50%, and diastolic dysfunction) and 60 patients with stage B HF (normal exercise tolerance with

66 Another independent group of 32 patients with stage C HF who recovered to New York Heart

67 n study enrolled 63 control subjects and 218 patients with stage C HF.

68 d to sunitinib or sorafenib vs placebo among patients with stages comparable to other high-risk adjuv

69 plantation is the most effective therapy for patients with Stage D heart failure with a median life e

70 coming an increasingly prevalent therapy for patients with Stage D heart failure with reduced ejectio

71 The AUC for patients with stage F0 versus stage F1-F2 was 0.93 (95%

72 , 1.09; 95% CI, 1.06-1.13; P < .001), and in patients with stage I (HR, 1.13; 95% CI, 1.08-1.18; P <

73 Middle-aged patients with stage I (odds ratio, 5.04; 95% CI, 2.30-11

74 OS was significantly inferior in patients with stage I (P < .0015) and stage IV disease (

75 ll survival, local control, and fibrosis for patients with stage I and II breast cancer who underwent

76 Among patients with stage I and II disease, young, healthy pat

77 We genotyped 240 miRNA-related SNPs in 535 patients with stage I and II NSCLCs to determine associa

78 Less than 10% of patients with stage I disease have a recurrence, and adj

79 e expected survival, the overall survival of patients with stage I disease paradoxically was signific

80 In patients with stage I disease treated with radiation the

81 R) status and grade significantly stratified patients with stage I disease with respect to RFS, DSS,

82 Between 1968 and 1974, 568 patients with stage I endometrial cancer were included.

83 ng Borrelia-specific antibodies in sera from patients with stage I LD.

84 nce of the tumor immune microenvironment for patients with stage I lung ADC and provides support for

85 gnificance of the immune microenvironment in patients with stage I lung adenocarcinoma (ADC).

86 ere evaluated using microarray data from 148 patients with stage I lung adenocarcinoma.

87 nt therapy and postoperative surveillance of patients with stage I lung adenocarcinoma.

88 Data were pooled from 2,552 patients with stage I lung cancer, 6,386 with bladder ca

89 nown about the role the Wnt pathway plays in patients with stage I lung cancer.

90 surgically resected lung tumor tissues of 64 patients with stage I NSCLC by using quantitative revers

91 Recommendations For standard operative risk patients with stage I NSCLC, SBRT is not recommended out

92 encing assay in an independent cohort of 143 patients with stage I NSCLC.

93 A surveillance policy for patients with stage I NSGCC is a safe approach associate

94 We recommend surveillance for patients with stage I NSGCC with immediate systemic trea

95 January 1, 1984, to December 31, 2007, 1,226 patients with stage I NSGCC, including high-risk patient

96 For patients with stage I or II bulky mediastinal HL, no sub

97 rt results of a planned subgroup analysis in patients with stage I or II bulky mediastinal Hodgkin ly

98 ival but enhances postoperative mortality in patients with stage I or II EC.

99 to assess whether NCRT improves outcomes for patients with stage I or II EC.

100 f incident cases of primary melanoma in 1621 patients with stage I or II melanoma in 2004 and 2008.

101 Fifty percent of patients with stage I pediatric MOGCT can be spared chem

102 alternative to transabdominal resection for patients with stage I rectal cancer.

103 A total of 1901 patients with stage I to II breast cancer (mean [SD] age

104 n of SNTI in sentinel lymph nodes and BMM in patients with stage I to III colon cancer and the progno

105 A total of 122 patients with stage I to III colon cancer were included.

106 on between the occurrence of SNTI and BMM in patients with stage I to III colon cancer.

107 prospective cohort of 2470 Kaiser Permanente patients with stage I to III CRC diagnosed from 2006 thr

108 In patients with stage I to III CRC, postoperative plasma v

109 ancer Registry, we studied a total of 24 843 patients with stage I to III invasive breast cancer diag

110 Methods Forty-five patients with stage I to III SCCAC and HIV infection rec

111 Methods Sixty-one patients with stage I to III SCCAC received CRT includin

112 le regional or distant recurrence in 6.4% of patients with stage I, 18.5% of stage II, and 33.1% of s

113 Analysis of patients with stage I, II, and III cancer revealed that

114 atients with stage II-IV NSCLC and in 50% of patients with stage I, with 96% specificity for mutant a

115 Forty-three (3.6%) patients with stage I-II disease received radiotherapy w

116 is, we reviewed pretreatment PET-CT scans of patients with stage I-II HL treated at our institution b

117 anscription PCR, and clinical outcome in 942 patients with stage I-III clear cell renal cell carcinom

118 score as a predictor of clinical outcome in patients with stage I-III clear cell renal cell carcinom

119 Among patients with stage I-III CRC, baseline red and processe

120 rkov model simulating the natural history of patients with stage I-III melanoma.

121 Twenty patients with stage I-III NSCLC and candidates for radic

122 stage, the 5-y overall survival was 67% for patients with stage I/II disease but only 31% for patien

123 A total of 2,672 patients with stage I/II melanoma were included.

124 section is the standard treatment option for patients with stage I/II pancreatic ductal adenocarcinom

125 ogy, and End Results) data were analyzed for patients with stage I/II pancreatic head cancers treated

126 result in an increase in average survival in patients with stage I/II PDA.

127 Patients with stages I to III breast cancer who were see

128 Fourteen patients with stage-I hypertension (66 +/- 5 (SD) years)

129 here were no significant differences between patients with stage IA and stage IB disease in 5- or 10-

130 on of an increased overall survival rate for patients with stage IA cancer treated via laparoscopy (l

131 ease had five times the risk of death versus patients with stage IA disease.

132 Adjuvant chemotherapy is not recommended for patients with stage IA disease.

133 Patients with stage IA LPHL in a single node that was co

134 esection has been increasingly used in older patients with stage IA lung cancer.

135 The long-term outcome of 256 patients with stage IA NLPHL was evaluated.

136 should be considered as standard of care for patients with stage IA NLPHL.

137 In total, 260 patients with stage IA to IIA mycosis fungoides who had

138 The performance of the panels in patients with stage IA-IIB pancreatic cancer was index I

139 purely on rupture were similar to rates for patients with stage IA/B, at 92% and 71%, respectively.

140 arkers remained prognostic for recurrence in patients with stages IA and IB disease as well as for pa

141 f progression compared with surgery alone in patients with stages IB to IIIA non-small-cell lung canc

142 nd tumor response to HPE was evaluated in 63 patients with stage IE/IIE1 HP-positive gastric DLBCL wh

143 y was associated with adverse outcomes among patients with stage II (DRFS: hazard ratio [HR], 1.20; 9

144 nd analysis plan, in archival specimens from patients with stage II and III colon cancer randomly ass

145 th both disease-free and overall survival in patients with stage II and III disease.

146 value of both proteins was also validated in patients with stage II and III tumors (p = 0.017 and p =

147 ncreased with higher scores, most notably in patients with stage II and IIIA/B disease.

148 l staging methods are inadequate to identify patients with stage II colon cancer (CC) who are at high

149 ict the development of distant metastasis of patients with stage II colon cancer and facilitates the

150 Recurrence Score assay has been validated in patients with stage II colon cancer from the Cancer and

151 djuvant therapy is recommended for high-risk patients with stage II colon cancer, but better tools to

152 Decisions regarding adjuvant therapy in patients with stage II colorectal cancer (CRC) have been

153 y on the benefit of adjuvant chemotherapy in patients with stage II colorectal cancers.

154 Importantly, analysis of patients with stage II CRC showed that disease-specific

155 A total of 1005 patients with stage II CRC were included in the 13 cohor

156 lapse-free survival and identify a subset of patients with stage II CRC who could gain substantial su

157 e validated in 11 independent cohorts of 767 patients with stage II CRC who did not receive adjuvant

158 Thirteen retrospective studies of patients with stage II CRC who had clinical follow-up an

159 In contrast, other patients with stage II disease and more than 45 y old ha

160 ithin the first 14 months post treatment for patients with stage II disease and within the first 4 ye

161 Patients with stage II disease receiving oxaliplatin did

162 ictions and facilitate the identification of patients with stage II disease who could gain survival b

163 etwork recommend against systemic staging in patients with stage II disease, our data suggest that PE

164 re lower in newer- versus old-era trials for patients with stage II disease, with no differences amon

165 pectively, representing 60%, 28%, and 12% of patients with stage II disease.

166 Liver transplantation in patients with stage II HCC and Child's A cirrhosis resul

167 Clinical feasibility was evaluated in patients with stage II lymphedema (three women; age rang

168 -21 vaccination does not improve outcome for patients with stage II melanoma.

169 the radiotherapy target volume suggest that patients with stage II or III non-small cell lung cancer

170 Among patients with stage II or III rectal cancer, the use of

171 sease severity, was confirmed at 10 years in patients with stage II to III colon cancer.

172 .41 (95% CI, 0.16 to 1.07), respectively, in patients with stage II to III dMMR and 0.50 (95% CI, 0.2

173 aterials Study eligibility criteria included patients with stage II to III NSCLC treated on one of fo

174 Data on 17600 patients with stage II to III rectal adenocarcinoma from

175 and 2009 were merged to create a data set of patients with stage II to IV disease treated with platin

176 A subset analysis was performed among patients with stage II to IV low-grade serous carcinoma

177 Patients with stage II-III cancer who received chemother

178 We screened 329 consecutive patients with stage II-III colorectal tumors with MSI wh

179 onsisting of four sequential study groups of patients with stage II-III locally advanced rectal cance

180 We detected ctDNA in 100% of patients with stage II-IV NSCLC and in 50% of patients w

181 Prior studies have suggested that patients with stage II/III colon cancer receive similar

182 ween September 2005 and December 2010, 2,073 patients with stage II/III rectal cancer were enrolled i

183 About 25% of patients with stages II-III colorectal tumors with MSI h

184 emotherapy is recommended for routine use in patients with stage IIA, IIB, or IIIA disease who have u

185 est that PET/CT might be valuable in younger patients with stage IIB and III disease.

186 The median OS for patients with stage IIB disease was 68 months, but patie

187 had slightly improved survival compared with patients with stage IIB, although patients diagnosed wit

188 We identified 3,808 patients with stage IIB, IIIA, or IIIB lung cancer by us

189 We report treatment outcomes of 346 patients with stage III AL amyloidosis from the United K

190 Patients with stage III and stage IV melanoma remain at

191 In both patients with stage III and stage IV melanoma, male pati

192 tion for Research and Treatment of Cancer in patients with stage III and two trials in patients with

193 This finding was particularly meaningful for patients with stage III BC, TNBC, and trastuzumab-treate

194 d using tumor samples from a separate set of patients with stage III cancer (n = 783).

195 aroscopic group than in the open group among patients with stage III cancer (P=0.078).

196 In 2841 patients with stage III cancer, AL was associated with b

197 pact of DPYD variants on fluorouracil AEs in patients with stage III CC treated with a fluorouracil,

198 il, and leucovorin chemotherapy (FOLFOX4) in patients with stage III colon cancer improved disease-fr

199 One in 5 patients with stage III colon cancer initiates AC within

200 gnostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with adjuva

201 Observational cohort study of patients with stage III colon cancer younger than 80 yea

202 Trial N0147, a randomized adjuvant trial of patients with stage III colon cancer, we assessed the re

203 antly reduced cancer recurrence and death in patients with stage III colon cancer.

204 tly reduced the risk of tumour recurrence in patients with stage III colon cancer.

205 the adjuvant chemotherapy treatment gap for patients with stage III colon cancer.

206 d with fluoropyrimidine improves survival in patients with stage III colon cancer.

207 gene (KRAS) in the primary tumor with SAR in patients with stage III colon carcinomas treated with ad

208 We did a double-blind, phase 3 trial in patients with stage III cutaneous melanoma (excluding ly

209 , double-blind, randomised, phase 3 trial in patients with stage III cutaneous melanoma (excluding ly

210 nts with stage I/II disease but only 31% for patients with stage III disease (log-rank P < 0.001).

211 o fluoropyrimidine-based adjuvant therapy in patients with stage III disease and underscore the need

212 Methods Patients with stage III disease at first melanoma diagno

213 h increasing stage (P for trend < .001), and patients with stage III disease had five times the risk

214 Studies that enrolled patients with stage III disease receiving radiotherapy (

215 Results A total of 535 patients with stage III disease were studied.

216 updated results support the use of FOLFOX in patients with stage III disease, including those with dM

217 Even in patients with stage III disease, only minimal gains in l

218 Although universally recommended for patients with stage III disease, there is no consensus a

219 f death from 2 to 6 years post treatment for patients with stage III disease, with no differences in

220 ered a standard adjuvant treatment option in patients with stage III disease.

221 II disease and within the first 4 years for patients with stage III disease.

222 Conclusion Most patients with stage III FHWT had good EFS/overall surviv

223 88 prospectively treated, centrally reviewed patients with stage III FHWT were treated with Regimen D

224 valuated clinical and biologic variables for patients with stage III FHWT without combined loss of he

225 criteria highly predictive of EFS and OS for patients with stage III FHWT.

226 Two hundred twenty-nine (5%) of 4,215 patients with stage III melanoma and 43 (1%) of 3,563 pa

227 a significantly lower risk of recurrence in patients with stage III melanoma with BRAF V600E or V600

228 compared adjuvant ipilimumab with placebo in patients with stage III melanoma.

229 f the most significant prognostic factors in patients with stage III melanoma.

230 Survival varies widely in patients with stage III melanoma.

231 analyzed data from childhood and adolescent patients with stage III MLBL (n = 42) and non-MLBL DLBCL

232 In this prospective study, 36 patients with stage III non-small cell lung cancers (NSC

233 than 60 Gy plus concurrent chemotherapy for patients with stage III non-small-cell lung cancer, and

234 Patients and Methods From 1996 to 2009, 127 patients with stage III NSCLC (Eastern Cooperative Oncol

235 Of 424 eligible patients with stage III NSCLC randomized, 360 (85%) cons

236 The authors retrospectively identified 195 patients with stage III NSCLC treated definitively with

237 treatment computed tomography images for 107 patients with stage III NSCLC.

238 sting for conventional prognostic factors in patients with stage III NSCLC.

239 Patients with stage III or IV glottic or supraglottic sq

240 radiation improves overall survival (OS) of patients with stage III or IV head and neck carcinoma (H

241 ional experience on overall survival (OS) in patients with stage III or IV HNC was investigated withi

242 Eligible patients with stage III or IV HNC were randomly assigned

243 xamine the effects of neoantigen vaccines on patients with stage III or IV melanoma and demonstrate i

244 Eleven patients with stage III or stage IV NSCLC underwent (18)

245 Patients with stage III resected lymph node or in-transi

246 We conducted a systematic review of patients with stage III to IV melanoma treated with immu

247 mmunotherapy tecemotide improves survival in patients with stage III unresectable non-small-cell lung

248 with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC.

249 Patients with stage III-IV OPC enrolled onto Radiation T

250 We serially sampled blood from patients with stage III-IV oropharyngeal cancer undergoi

251 Twenty patients with stage III-IVa HNSCC prospectively underwen

252 sease, MSS outcomes were similar to those of patients with stage IIIA disease after 3 and 5 years of

253 In patients with stage IIIA N2 disease, adjuvant radiation

254 Treatment-naive patients with stage IIIB or IV NSCLC and a common EGFR m

255 Among patients with stage IIIB tumors, 5-year survival rates w

256 T-VEC efficacy was most pronounced in patients with stage IIIB, IIIC, or IVM1a disease and in

257 rospective data from 2 centers identified 97 patients with stage IIIB/IIIC extremity melanoma undergo

258 ised, open-label, phase 3 study in untreated patients with stage IIIB/IV ALK-rearranged non-squamous

259 Patients with stage IIIB/IV nonsquamous NSCLC were rando

260 Methods Patients with stage IIIB/IV squamous (N = 272) or nonsqu

261 ion rates within 30 days of index surgery in patients with stage IIIC/IV ovarian, primary peritoneal,

262 Patients with stages IIIC and IV disease who received NA

263 ies in early supportive medication use among patients with stage IV breast cancer.

264 Patients with stage IV chemotherapy-naive melanoma (n =

265 ve, single-group, open-label, phase 2 trial, patients with stage IV chemotherapy-refractory, histolog

266 We identified 1004 patients with stage IV colon cancer subsequently hospita

267 In this large population of patients with stage IV colon cancer, BO after diagnosis

268 biologic agents, primary tumor resection for patients with stage IV colorectal cancer (CRC) may not b

269 The majority of patients with stage IV CRC had undergone primary tumor r

270 Of the 64,157 patients with stage IV CRC, 43,273 (67.4%) had undergone

271 se immune profiling of peripheral blood from patients with stage IV melanoma before and after treatme

272 with stage III melanoma and 43 (1%) of 3,563 patients with stage IV melanoma had at least one NPM aft

273 In this first-in-human strategy, 10 patients with stage IV melanoma received the MART1-speci

274 ine, immune, and neurobehavioral changes, 20 patients with Stage IV melanoma were randomized to eithe

275 ed the first treatment improving survival of patients with stage IV melanoma.

276 in patients with stage III and two trials in patients with stage IV melanoma.

277 lumab, an anti-PD-L1 monoclonal antibody, in patients with stage IV Merkel cell carcinoma that had pr

278 we enrolled previously treated and untreated patients with stage IV metastatic BRAF(V600E)-positive N

279 ad a strong prognostic impact, especially in patients with stage IV mucinous adenocarcinoma.

280 2015 ASCO guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC

281 Patients with stage IV non-small-cell lung cancer (NSCLC

282 umab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC

283 n increases survival of previously untreated patients with stage IV non-squamous NSCLC.

284 Use of SBRT with erlotinib for unselected patients with stage IV NSCLC as a second- or subsequent

285 tario) perspective and a lifetime horizon in patients with stage IV NSCLC with nonsquamous histology.

286 There is no cure for patients with stage IV NSCLC.

287 mproves survival as second-line treatment of patients with stage IV NSCLC.

288 Twenty-five patients with stage IV uveal melanoma who had received 0

289 atified analysis, the hazard ratio comparing patients with stage IV versus stage I LA LGE was 1.67 (9

290 Patients with stage IV/locally recurrent TNBC who had re

291 The 3-year overall survival rates of the patients with stage IVAnon-n1, stage n1, and stage IVB w

292 lity rate was significantly increased in all patients with stage IVC disease.

293 ocal response) to planned neck dissection in patients with stage N2 or N3 disease.

294 Patients with staged revascularization, TLR, and other u

295 Among the patients with stage T1 disease, the risk of distant recu

296 Patients with stage T2 multilesion angiosarcomas of the

297 nced computed tomographic (CT) studies in 36 patients with stage T2 or greater esophageal tumors who

298 ant chemoradiotherapy and local excision for patients with stage T2N0 rectal cancer.

299 , polo-like kinase 1 (Plk1), and survivin in patients with stage Ta and T1 urothelial carcinomas.

300 We identified patients with stage wet IIIB or IV lung cancer who recei